LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 1570

Search options

  1. Article: Host-cell Interactions of Engineered T cell Micropharmacies.

    Bourne, Christopher M / Wallisch, Patrick / Dacek, Megan / Gardner, Thomas / Pierre, Stephanie / Vogt, Kristen / Corless, Broderick C / Bah, Mamadou A / Romero Pichardo, Jesus / Charles, Angel / Kurtz, Keifer G / Tan, Derek S / Scheinberg, David A

    bioRxiv : the preprint server for biology

    2023  

    Abstract: Genetically engineered, cytotoxic, adoptive T cells localize to antigen positive cancer cells ... of most solid tumor types. More effective, multifunctional engineered T cells are in development ... into chimeric antigen receptor (CAR) T cells, endowing them with an orthogonal killing mechanism to conventional ...

    Abstract Genetically engineered, cytotoxic, adoptive T cells localize to antigen positive cancer cells inside patients, but tumor heterogeneity and multiple immune escape mechanisms have prevented the eradication of most solid tumor types. More effective, multifunctional engineered T cells are in development to overcome the barriers to the treatment of solid tumors, but the interactions of these highly modified cells with the host are poorly understood. We previously engineered prodrug-activating enzymatic functions into chimeric antigen receptor (CAR) T cells, endowing them with an orthogonal killing mechanism to conventional T-cell cytotoxicity. These drug-delivering cells, termed Synthetic Enzyme-Armed KillER (SEAKER) cells, demonstrated efficacy in mouse lymphoma xenograft models. However, the interactions of an immunocompromised xenograft with such complex engineered T cells are distinct from those in an immunocompetent host, precluding an understanding of how these physiologic processes may affect the therapy. Here, we also expand the repertoire of SEAKER cells to target solid-tumor melanomas in syngeneic mouse models using specific targeting with TCR-engineered T cells. We demonstrate that SEAKER cells localize specifically to tumors, and activate bioactive prodrugs, despite host immune responses. We additionally show that TCR-engineered SEAKER cells are efficacious in immunocompetent hosts, demonstrating that the SEAKER platform is applicable to many adoptive cell therapies.
    Language English
    Publishing date 2023-05-01
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.04.05.535717
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Host Interactions with Engineered T-cell Micropharmacies.

    Bourne, Christopher M / Wallisch, Patrick / Dacek, Megan M / Gardner, Thomas J / Pierre, Stephanie / Vogt, Kristen / Corless, Broderick C / Bah, Mamadou A / Romero-Pichardo, Jesus E / Charles, Angel / Kurtz, Keifer G / Tan, Derek S / Scheinberg, David A

    Cancer immunology research

    2023  Volume 11, Issue 9, Page(s) 1253–1265

    Abstract: Genetically engineered, cytotoxic, adoptively transferred T cells localize to antigen-positive ... the eradication of most solid tumor types. More effective, multifunctional engineered T cells are in development ... into chimeric antigen receptor (CAR) T cells, endowing them with a killing mechanism orthogonal to conventional ...

    Abstract Genetically engineered, cytotoxic, adoptively transferred T cells localize to antigen-positive cancer cells inside patients, but tumor heterogeneity and multiple immune escape mechanisms have prevented the eradication of most solid tumor types. More effective, multifunctional engineered T cells are in development to overcome the barriers to the treatment of solid tumors, but the interactions of these highly modified cells with the host are poorly understood. We previously engineered prodrug-activating enzymatic functions into chimeric antigen receptor (CAR) T cells, endowing them with a killing mechanism orthogonal to conventional T-cell cytotoxicity. These drug-delivering cells, termed Synthetic Enzyme-Armed KillER (SEAKER) cells, demonstrated efficacy in mouse lymphoma xenograft models. However, the interactions of an immunocompromised xenograft with such complex engineered T cells are distinct from those in an immunocompetent host, precluding an understanding of how these physiologic processes may affect the therapy. Herein, we expanded the repertoire of SEAKER cells to target solid-tumor melanomas in syngeneic mouse models using specific targeting with T-cell receptor (TCR)-engineered T cells. We demonstrate that SEAKER cells localized specifically to tumors, and activated bioactive prodrugs, despite host immune responses. We additionally show that TCR-engineered SEAKER cells were efficacious in immunocompetent hosts, demonstrating that the SEAKER platform is applicable to many adoptive cell therapies.
    MeSH term(s) Mice ; Animals ; Humans ; Immunotherapy, Adoptive ; T-Lymphocytes, Cytotoxic ; Genetic Engineering ; Melanoma ; Receptors, Antigen, T-Cell/genetics
    Chemical Substances Receptors, Antigen, T-Cell
    Language English
    Publishing date 2023-07-17
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2732489-8
    ISSN 2326-6074 ; 2326-6066
    ISSN (online) 2326-6074
    ISSN 2326-6066
    DOI 10.1158/2326-6066.CIR-22-0879
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications.

    Kurtz, Keifer / Eibler, Laura / Dacek, Megan M / Carter, Lukas M / Veach, Darren R / Lovibond, Samantha / Reynaud, Emma / Qureshy, Sarah / McDevitt, Michael R / Bourne, Christopher / Monette, Sebastien / Punzalan, Blesida / Khayat, Shireen / Verma, Svena / Kesner, Adam L / Cheung, Nai-Kong V / Schöder, Heiko / Gajecki, Leah / Cheal, Sarah M /
    Larson, Steven M / Scheinberg, David A / Krebs, Simone

    Theranostics

    2023  Volume 13, Issue 15, Page(s) 5469–5482

    Abstract: Rationale: ...

    Abstract Rationale:
    MeSH term(s) Radioimmunotherapy ; Positron Emission Tomography Computed Tomography ; Tissue Distribution ; Immunotherapy, Adoptive/methods ; Radioisotopes/metabolism ; Antineoplastic Agents/metabolism ; T-Lymphocytes/metabolism
    Chemical Substances Radioisotopes ; Antineoplastic Agents
    Language English
    Publishing date 2023-10-08
    Publishing country Australia
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2592097-2
    ISSN 1838-7640 ; 1838-7640
    ISSN (online) 1838-7640
    ISSN 1838-7640
    DOI 10.7150/thno.87489
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies.

    Klatt, Martin G / Dao, Tao / Yang, Zhiyuan / Liu, Jianying / Mun, Sung Soo / Dacek, Megan M / Luo, Hanzhi / Gardner, Thomas J / Bourne, Christopher / Peraro, Leila / Aretz, Zita E H / Korontsvit, Tanya / Lau, Michael / Kharas, Michael G / Liu, Cheng / Scheinberg, David A

    Blood

    2022  Volume 140, Issue 8, Page(s) 861–874

    Abstract: Target identification for chimeric antigen receptor (CAR) T-cell therapies remains challenging due ... of cell surface HLA provide a wide pool of potential antigens targetable through T-cell receptor mimic ... associated NDC80 gene. CAR T cells directed against the ALNEQIARL:HLA-A*02 complex exhibited high ...

    Abstract Target identification for chimeric antigen receptor (CAR) T-cell therapies remains challenging due to the limited repertoire of tumor-specific surface proteins. Intracellular proteins presented in the context of cell surface HLA provide a wide pool of potential antigens targetable through T-cell receptor mimic antibodies. Mass spectrometry (MS) of HLA ligands from 8 hematologic and nonhematologic cancer cell lines identified a shared, non-immunogenic, HLA-A*02-restricted ligand (ALNEQIARL) derived from the kinetochore-associated NDC80 gene. CAR T cells directed against the ALNEQIARL:HLA-A*02 complex exhibited high sensitivity and specificity for recognition and killing of multiple cancer types, especially those of hematologic origin, and were efficacious in mouse models against a human leukemia and a solid tumor. In contrast, no toxicities toward resting or activated healthy leukocytes as well as hematopoietic stem cells were observed. This shows how MS can inform the design of broadly reactive therapeutic T-cell receptor mimic CAR T-cell therapies that can target multiple cancer types currently not druggable by small molecules, conventional CAR T cells, T cells, or antibodies.
    MeSH term(s) Animals ; Antibodies/metabolism ; Cytoskeletal Proteins/metabolism ; HLA-A Antigens ; Hematologic Neoplasms/metabolism ; Hematologic Neoplasms/therapy ; Humans ; Immunotherapy, Adoptive/methods ; Mice ; Neoplasms ; Receptors, Antigen, T-Cell ; T-Lymphocytes
    Chemical Substances Antibodies ; Cytoskeletal Proteins ; HLA-A Antigens ; NDC80 protein, human ; Receptors, Antigen, T-Cell
    Language English
    Publishing date 2022-04-12
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2021012882
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker.

    Dacek, Megan M / Kurtz, Keifer G / Wallisch, Patrick / Pierre, Stephanie A / Khayat, Shireen / Bourne, Christopher M / Gardner, Thomas J / Vogt, Kristen C / Aquino, Nica / Younes, Anas / Scheinberg, David A

    Blood

    2023  Volume 141, Issue 16, Page(s) 2003–2015

    Abstract: Chimeric antigen receptor (CAR) T-cell therapy has shown success in the treatment ... of hematopoietic malignancies; however, relapse remains a significant issue. To overcome this, we engineered "Orexi" CAR T ... with an orthogonally targeted monoclonal antibody. Traditional CAR T cells plus the antibody had an additive effect ...

    Abstract Chimeric antigen receptor (CAR) T-cell therapy has shown success in the treatment of hematopoietic malignancies; however, relapse remains a significant issue. To overcome this, we engineered "Orexi" CAR T cells to locally secrete a high-affinity CD47 blocker, CV1, at the tumor and treated tumors in combination with an orthogonally targeted monoclonal antibody. Traditional CAR T cells plus the antibody had an additive effect in xenograft models, and this effect was potentiated by CAR T-cell local CV1 secretion. Furthermore, OrexiCAR-secreted CV1 reversed the immunosuppression of myelomonocytoid cells both in vitro and within the tumor microenvironment. Local secretion of the CD47 inhibitor bypasses the CD47 sink found on all cells in the body and may prevent systemic toxicities. This combination of CAR T-cell therapy, local CD47 blockade, and orthogonal antibody may be a combinatorial strategy to overcome the limitations of each monotherapy.
    MeSH term(s) Humans ; CD47 Antigen ; Neoplasm Recurrence, Local ; Neoplasms/pathology ; T-Lymphocytes ; Immunotherapy, Adoptive ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal/pharmacology ; Tumor Microenvironment
    Chemical Substances CD47 Antigen ; Antibodies, Monoclonal ; CD47 protein, human
    Language English
    Publishing date 2023-01-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2022016101
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function.

    Sugiura, Ayaka / Andrejeva, Gabriela / Voss, Kelsey / Heintzman, Darren R / Xu, Xincheng / Madden, Matthew Z / Ye, Xiang / Beier, Katherine L / Chowdhury, Nowrin U / Wolf, Melissa M / Young, Arissa C / Greenwood, Dalton L / Sewell, Allison E / Shahi, Shailesh K / Freedman, Samantha N / Cameron, Alanna M / Foerch, Patrik / Bourne, Tim / Garcia-Canaveras, Juan C /
    Karijolich, John / Newcomb, Dawn C / Mangalam, Ashutosh K / Rabinowitz, Joshua D / Rathmell, Jeffrey C

    Immunity

    2021  Volume 55, Issue 1, Page(s) 65–81.e9

    Abstract: Antigenic stimulation promotes T cell metabolic reprogramming to meet increased biosynthetic ... methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) regulates de novo purine synthesis and signaling in activated T cells to promote ... proliferation and inflammatory cytokine production. In pathogenic T helper-17 (Th17) cells, MTHFD2 prevented ...

    Abstract Antigenic stimulation promotes T cell metabolic reprogramming to meet increased biosynthetic, bioenergetic, and signaling demands. We show that the one-carbon (1C) metabolism enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) regulates de novo purine synthesis and signaling in activated T cells to promote proliferation and inflammatory cytokine production. In pathogenic T helper-17 (Th17) cells, MTHFD2 prevented aberrant upregulation of the transcription factor FoxP3 along with inappropriate gain of suppressive capacity. MTHFD2 deficiency also promoted regulatory T (Treg) cell differentiation. Mechanistically, MTHFD2 inhibition led to depletion of purine pools, accumulation of purine biosynthetic intermediates, and decreased nutrient sensor mTORC1 signaling. MTHFD2 was also critical to regulate DNA and histone methylation in Th17 cells. Importantly, MTHFD2 deficiency reduced disease severity in multiple in vivo inflammatory disease models. MTHFD2 is thus a metabolic checkpoint to integrate purine metabolism with pathogenic effector cell signaling and is a potential therapeutic target within 1C metabolism pathways.
    MeSH term(s) Animals ; Cell Differentiation ; Cytokines/metabolism ; DNA Methylation ; Disease Models, Animal ; Humans ; Inflammation/immunology ; Inflammation Mediators/metabolism ; Lymphocyte Activation ; Mechanistic Target of Rapamycin Complex 1/metabolism ; Methylenetetrahydrofolate Dehydrogenase (NADP)/genetics ; Methylenetetrahydrofolate Dehydrogenase (NADP)/metabolism ; Mice ; Mice, Transgenic ; Mutation/genetics ; Purines/biosynthesis ; Signal Transduction ; T-Lymphocytes, Regulatory/immunology ; Th17 Cells/immunology
    Chemical Substances Cytokines ; Inflammation Mediators ; Purines ; Methylenetetrahydrofolate Dehydrogenase (NADP) (EC 1.5.1.5) ; Mechanistic Target of Rapamycin Complex 1 (EC 2.7.11.1)
    Language English
    Publishing date 2021-11-11
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1217235-2
    ISSN 1097-4180 ; 1074-7613
    ISSN (online) 1097-4180
    ISSN 1074-7613
    DOI 10.1016/j.immuni.2021.10.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Boosting of vaginal HSV-2-specific B and T cell responses by intravaginal therapeutic immunization results in diminished recurrent HSV-2 disease.

    Bourne, Nigel / Keith, Celeste A / Miller, Aaron L / Pyles, Richard B / Cohen, Gary / Milligan, Gregg N

    Journal of virology

    2023  Volume 97, Issue 9, Page(s) e0066923

    Abstract: Boosting herpes simplex virus (HSV)-specific immunity in the genital tissues of HSV-positive individuals to increase control of HSV-2 recurrent disease and virus shedding is an important goal of therapeutic immunization and would impact HSV-2 ... ...

    Abstract Boosting herpes simplex virus (HSV)-specific immunity in the genital tissues of HSV-positive individuals to increase control of HSV-2 recurrent disease and virus shedding is an important goal of therapeutic immunization and would impact HSV-2 transmission. Experimental therapeutic HSV-2 vaccines delivered by a parenteral route have resulted in decreased recurrent disease in experimental animals. We used a guinea pig model of HSV-2 infection to test if HSV-specific antibody and cell-mediated responses in the vaginal mucosa would be more effectively increased by intravaginal (Ivag) therapeutic immunization compared to parenteral immunization. Therapeutic immunization with HSV glycoproteins and CpG adjuvant increased glycoprotein-specific IgG titers in vaginal secretions and serum to comparable levels in Ivag- and intramuscular (IM)-immunized animals. However, the mean numbers of HSV glycoprotein-specific antibody secreting cells (ASCs) and IFN-γ SCs were greater in Ivag-immunized animals demonstrating superior boosting of immunity in the vaginal mucosa compared to parenteral immunization. Therapeutic Ivag immunization also resulted in a significant decrease in the cumulative mean lesion days compared to IM immunization. There was no difference in the incidence or magnitude of HSV-2 shedding in either therapeutic immunization group compared to control-treated animals. Collectively, these data demonstrated that Ivag therapeutic immunization was superior compared to parenteral immunization to boost HSV-2 antigen-specific ASC and IFN-γ SC responses in the vagina and control recurrent HSV-2 disease. These results suggest that novel antigen delivery methods providing controlled release of optimized antigen/adjuvant combinations in the vaginal mucosa would be an effective approach for therapeutic HSV vaccines. IMPORTANCE HSV-2 replicates in skin cells before it infects sensory nerve cells where it establishes a lifelong but mostly silent infection. HSV-2 occasionally reactivates, producing new virus which is released back at the skin surface and may be transmitted to new individuals. Some HSV-specific immune cells reside at the skin site of the HSV-2 infection that can quickly activate and clear new virus. Immunizing people already infected with HSV-2 to boost their skin-resident immune cells and rapidly control the new HSV-2 infection is logical, but we do not know the best way to administer the vaccine to achieve this goal. In this study, a therapeutic vaccine given intravaginally resulted in significantly better protection against HSV-2 disease than immunization with the same vaccine by a conventional route. Immunization by the intravaginal route resulted in greater stimulation of vaginal-resident, virus-specific cells that produced antibody and produced immune molecules to rapidly clear virus.
    MeSH term(s) Animals ; Female ; Guinea Pigs ; Humans ; Adjuvants, Immunologic ; Antibodies, Viral ; Glycoproteins/metabolism ; Herpes Genitalis/prevention & control ; Herpes Simplex/metabolism ; Herpesvirus 1, Cercopithecine ; Herpesvirus 2, Human/physiology ; Immunization ; T-Lymphocytes ; Vagina/immunology ; Vagina/virology
    Chemical Substances Adjuvants, Immunologic ; Antibodies, Viral ; Glycoproteins
    Language English
    Publishing date 2023-09-01
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 80174-4
    ISSN 1098-5514 ; 0022-538X
    ISSN (online) 1098-5514
    ISSN 0022-538X
    DOI 10.1128/jvi.00669-23
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Engineering CAR-T cells to activate small-molecule drugs in situ.

    Gardner, Thomas J / Lee, J Peter / Bourne, Christopher M / Wijewarnasuriya, Dinali / Kinarivala, Nihar / Kurtz, Keifer G / Corless, Broderick C / Dacek, Megan M / Chang, Aaron Y / Mo, George / Nguyen, Kha M / Brentjens, Renier J / Tan, Derek S / Scheinberg, David A

    Nature chemical biology

    2021  Volume 18, Issue 2, Page(s) 216–225

    Abstract: Chimeric antigen receptor (CAR)-T cells represent a major breakthrough in cancer therapy, wherein ... a patient's own T cells are engineered to recognize a tumor antigen, resulting in activation of a local ... cytotoxic immune response. However, CAR-T cell therapies are currently limited to the treatment of B cell ...

    Abstract Chimeric antigen receptor (CAR)-T cells represent a major breakthrough in cancer therapy, wherein a patient's own T cells are engineered to recognize a tumor antigen, resulting in activation of a local cytotoxic immune response. However, CAR-T cell therapies are currently limited to the treatment of B cell cancers and their effectiveness is hindered by resistance from antigen-negative tumor cells, immunosuppression in the tumor microenvironment, eventual exhaustion of T cell immunologic functions and frequent severe toxicities. To overcome these problems, we have developed a novel class of CAR-T cells engineered to express an enzyme that activates a systemically administered small-molecule prodrug in situ at a tumor site. We show that these synthetic enzyme-armed killer (SEAKER) cells exhibit enhanced anticancer activity with small-molecule prodrugs, both in vitro and in vivo in mouse tumor models. This modular platform enables combined targeting of cellular and small-molecule therapies to treat cancers and potentially a variety of other diseases.
    MeSH term(s) Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/therapeutic use ; Drug Delivery Systems ; Female ; HEK293 Cells ; Humans ; Male ; Mice ; Mice, Inbred C57BL ; Neoplasms/therapy ; Neoplasms, Experimental ; Prodrugs ; Receptors, Chimeric Antigen ; T-Lymphocytes ; Tumor Microenvironment ; Xenograft Model Antitumor Assays
    Chemical Substances Antineoplastic Agents ; Prodrugs ; Receptors, Chimeric Antigen
    Language English
    Publishing date 2021-12-30
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2202962-X
    ISSN 1552-4469 ; 1552-4450
    ISSN (online) 1552-4469
    ISSN 1552-4450
    DOI 10.1038/s41589-021-00932-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Development of an anti-guinea pig CD4 monoclonal antibody for depletion of CD4+ T cells in vivo.

    Banasik, Brianne N / Perry, Clarice L / Keith, Celeste A / Bourne, Nigel / Schäfer, Hubert / Milligan, Gregg N

    Journal of immunological methods

    2019  Volume 474, Page(s) 112654

    Abstract: ... A rat IgG2a mAb specific for guinea pig CD4 has previously been described and was shown to inhibit T ... cell proliferation, but was inefficient at depleting CD4+ T cells in vivo. We hypothesized that the in vivo CD4+ T ... significantly depleted CD4+ T cells from secondary lymphoid tissue of guinea pigs. Further, treatment ...

    Abstract The guinea pig serves as a useful animal model for a number of human diseases and has played an important role during development and testing of experimental vaccines and disease therapies. However, the availability of reagents to examine the immunological response in this species is very limited. Monoclonal antibodies (mAb) specific for cell surface proteins or products of immune cells have been useful tools for characterizing and quantifying immune responses in humans and in murine models of human disease, but very few similar reagents are available for characterizing and manipulating the immune response of guinea pigs. A rat IgG2a mAb specific for guinea pig CD4 has previously been described and was shown to inhibit T cell proliferation, but was inefficient at depleting CD4+ T cells in vivo. We hypothesized that the in vivo CD4+ T cell depletion function of this mAb could be improved by expression of the rat IgG2b heavy chain. We show that the purified mAb from an IgG2b class-switch variant, but not the parental IgG2a mAb, significantly depleted CD4+ T cells from secondary lymphoid tissue of guinea pigs. Further, treatment of guinea pigs with the IgG2b mAb at 2.0 mg/kg resulted in depletion of CD4+ T cells from peripheral blood and spleen. The use of this modified antibody to specifically alter the immune response of guinea pigs should prove useful in a number of guinea pig infectious disease models.
    MeSH term(s) Animals ; Antibodies, Monoclonal/biosynthesis ; Antibodies, Monoclonal/genetics ; Antibodies, Monoclonal/immunology ; Antibody Specificity ; CD4-Positive T-Lymphocytes/immunology ; Female ; Guinea Pigs ; Hybridomas ; Immunoglobulin Class Switching ; Immunoglobulin G/biosynthesis ; Immunoglobulin G/genetics ; Immunoglobulin G/immunology ; Lymphocyte Depletion/methods ; Rats ; Spleen/immunology
    Chemical Substances Antibodies, Monoclonal ; Immunoglobulin G
    Language English
    Publishing date 2019-08-14
    Publishing country Netherlands
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 120142-6
    ISSN 1872-7905 ; 0022-1759
    ISSN (online) 1872-7905
    ISSN 0022-1759
    DOI 10.1016/j.jim.2019.112654
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: The SW(HEL) system for high-resolution analysis of in vivo antigen-specific T-dependent B cell responses.

    Brink, R / Paus, D / Bourne, K / Hermes, J R / Gardam, S / Phan, T G / Chan, T D

    Methods in molecular biology (Clifton, N.J.)

    2015  Volume 1291, Page(s) 103–123

    Abstract: T cell-dependent B cell responses generate optimal antibodies to combat foreign antigens. Naïve ... antigen. This system can provide a valuable measure of the functional capabilities of T follicular ...

    Abstract T cell-dependent B cell responses generate optimal antibodies to combat foreign antigens. Naïve B cells responding to antigen undergo a complex series of differentiation events and cell fate decisions to provide long-lived memory B cells and plasma cells. Historically, B cell biologists have been challenged by the task of investigating rare antigen-specific B cells in an in vivo setting such that their interactions with antigen, regulation and migration may be accurately tracked. We have developed the SW(HEL) experimental system capable of accurately monitoring B cells that interact with a protein antigen and then subsequently undergo isotype switching, somatic hypermutation, and affinity maturation within germinal centers (GC) to generate high-affinity antibodies. Here we provide a comprehensive description of the procedures involved in establishing and using the SW(HEL) system to assess B cell responses to a foreign antigen. This system can provide a valuable measure of the functional capabilities of T follicular helper cells, whose role is ultimately to support and shape long-term humoral immunity.
    MeSH term(s) Adoptive Transfer ; Animals ; Antibodies/blood ; Antibody Affinity/immunology ; B-Lymphocytes/immunology ; Chickens ; Enzyme-Linked Immunosorbent Assay ; Epitopes/immunology ; Erythrocytes/metabolism ; Flow Cytometry ; Fluorescent Antibody Technique ; Genotyping Techniques ; Immunologic Techniques/methods ; Lymphocyte Subsets/immunology ; Mice, Transgenic ; Muramidase/metabolism ; Polymerase Chain Reaction ; Recombinant Proteins/metabolism ; Sheep ; Somatic Hypermutation, Immunoglobulin ; Spleen/cytology ; Staining and Labeling ; T-Lymphocytes/immunology
    Chemical Substances Antibodies ; Epitopes ; Recombinant Proteins ; Muramidase (EC 3.2.1.17)
    Language English
    Publishing date 2015
    Publishing country United States
    Document type Journal Article
    ISSN 1940-6029
    ISSN (online) 1940-6029
    DOI 10.1007/978-1-4939-2498-1_9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top